Magnetic resonance contrast agents: From the bench to the patient

被引:29
作者
Lorusso, V
Pascolo, L
Fernetti, C
Anelli, PL
Uggeri, F
Tiribelli, C
机构
[1] Ctr Studi Fegato, I-34012 Trieste, Italy
[2] Univ Trieste, Dept BBCM, I-34012 Trieste, Italy
[3] Bracco Imaging SpA, Ctr Ric Milano, Milan, Italy
关键词
MRI contrast agent; plasma protein binding; membrane transport; elimination; liver; kidney; ABC transport proteins; imaging technology; diagnosis; patients;
D O I
10.2174/138161205774913336
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Magnetic Resonance Imaging is gaining a prominent role in the routine clinical investigation. To further improve this technique it is crucial that contrast agents are developed with more optimal organ specificity. This will not only result in a better diagnostic efficiency but also in a reduction of the amount of the agent administered. A combination of techniques has been employed to increase the target selectivity of the contrast agent and thereby the feasibility to visualize different organs. The organ targeting is based on the understanding of the mechanisms involved in the interaction of the agent with plasma proteins (albumin in particular) as well as the different membrane transporters involved in the uptake and in the excretion of the agent from the organ. The physicochemical properties of the contrast agents play a major role in the interaction with these various proteins. In this review we address the relationship between the structure of the contrast agents and their binding to different plasma proteins and membrane transporters in different organs, with special reference to the liver and kidney. The present and potentially future applications of these concepts in the clinical setting are also discussed.
引用
收藏
页码:4079 / 4098
页数:20
相关论文
共 122 条
[1]   Molecular characterization of human and rat organic anion transporter OATP-D [J].
Adachi, H ;
Suzuki, T ;
Abe, M ;
Asano, N ;
Mizutamari, H ;
Tanemoto, M ;
Nishio, T ;
Onogawa, T ;
Toyohara, T ;
Kasai, S ;
Satoh, F ;
Suzuki, M ;
Tokui, T ;
Unno, M ;
Shimosegawa, T ;
Matsuno, S ;
Ito, S ;
Abe, T .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2003, 285 (06) :F1188-F1197
[2]   Lanthanide(III) chelates for NMR biomedical applications [J].
Aime, S ;
Botta, M ;
Fasano, M ;
Terreno, E .
CHEMICAL SOCIETY REVIEWS, 1998, 27 (01) :19-29
[3]   Conjugates of gadolinium complexes to bile acids as hepatocyte-directed contrast agents for magnetic resonance Imaging [J].
Anelli, PL ;
Lattuada, L ;
Lorusso, V ;
Lux, G ;
Morisetti, A ;
Morosini, P ;
Serleti, M ;
Uggeri, F .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) :3629-3641
[4]  
Anelli PL, 1997, ACTA RADIOL, V38, P125
[5]  
Anelli PL, 1996, GAZZ CHIM ITAL, V126, P89
[6]  
[Anonymous], 2001, ACOUSTIC CHARACTERIZ
[7]   Nuclear medicine: from photon's to physiology [J].
Bailey, DL ;
Adamson, KL .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (11) :903-916
[8]   Abdominal MR: liver and pancreas [J].
Bartolozzi, C ;
Lencioni, R ;
Donati, F ;
Cioni, D .
EUROPEAN RADIOLOGY, 1999, 9 (08) :1496-1512
[9]   The role of half-transporters in multidrug resistance [J].
Bates, SE ;
Robey, R ;
Miyake, K ;
Rao, K ;
Ross, DD ;
Litman, T .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2001, 33 (06) :503-511
[10]   Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs [J].
Benness, G ;
Khangure, M ;
Morris, I ;
Warwick, A ;
Burrows, P ;
Vogler, H ;
Weinmann, HJ .
INVESTIGATIVE RADIOLOGY, 1996, 31 (04) :211-217